ClinicalTrials.gg

Program

dirloctocogene samoparvovec

A development code. Also written as “SPK-8011QQ”.

Its studies are mostly in Hemophilia A, led by Hoffmann-La Roche.

Furthest: phase 2, since Oct 28, 20251 company-led study, 1 open or runningNext primary completion: Apr 30, 2032 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche11 open or runningphase 2since Oct 28, 2025Oct 28, 2025Apr 30, 2032phase 2 · NCT07226206
  • Named in Hoffmann-La Roche’s own pipeline as RG6797 dirloctocogene samoparvovec, phase 2, as of Oct 22, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 28, 2025First study: phase 2 study in Hemophilia AFirst studyNCT07226206 · 5 planned · United States

Ahead

  1. Apr 30, 2032Primary completion: phase 2 study in Hemophilia ANCT07226206

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07226206Hemophilia A · United States2RecruitingApr 30, 20325

How it is read

Names in the registry

  • “SPK-8011QQ”, 1 entry

Codes read as this program: SPK8011QQ.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.